GSK 2256098
Alternative Names: 2256098; GSK-2256098Latest Information Update: 04 Jul 2024
At a glance
- Originator GlaxoSmithKline
- Developer Alliance for Clinical Trials in Oncology; GSK; National Cancer Institute (USA)
- Class Antineoplastics
- Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Meningioma; Pancreatic cancer
- No development reported Malignant-mesothelioma; Pulmonary arterial hypertension; Solid tumours
Most Recent Events
- 31 May 2024 Efficacy and adverse event data from a phase II trial in Meningioma presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 27 Oct 2022 GlaxoSmithKline completes a phase II trial in Pancreatic cancer (Combination therapy, Late-stage disease) in Canada (PO) (NCT02428270)
- 30 Sep 2021 Phase-II development in Meningioma is ongoing in USA (PO) (NCT02523014)